TET2 and acute myeloid leukemia: Interestingly, a subset of acute myeloid leukemia and glioma patients without TET2 mutations bear isocitrate dehydrogenases 1 and 2 (IDH1/2) mutations, which produce D-2-hydroxyglutarate to competitively inhibit TET2 activity22,23.